medigraphic.com

2000, Número 3

Siguiente >>

Arch Cardiol Mex 2000; 70 (3)


Las plaquetas y la enfermedad cardiaca: ¿Cuánto más puede la ciencia básica influir en la práctica clínica?

Flores NA

Idioma: Español
Referencias bibliográficas: 71
Paginas: 213-218
Archivo PDF: 147.43 Kb.


FRAGMENTO

En los años recientes ha cobrado gran interés el papel patofisiológico de las plaquetas en la enfermedad cardiovascular. Esto ha dado origen a una comprensión más profunda de los mecanismos implicados en el proceso de la enfermedad y es en gran parte el resultado del esfuerzo concertado y de la cooperación entre los campos de la ciencia básica y la medicina clínica. Las ventajas de esto han sido inmensas, en términos del número de vidas salvadas y del conocimiento ganado, y ellas demuestran el valor de un enfoque integral. La enfermedad cardiaca es endémica y es la causa principal de la muerte en los países desarrollados, a pesar de los esfuerzos médicos y científicos durante las últimas décadas. El futuro de la investigación cardiovascular requiere un enfoque nuevo e integral para reducir el riesgo de la enfermedad cardiaca.1 El propósito de esta revisión es esbozar en qué manera la ciencia básica está contribuyendo a tratamientos más eficaces para las enfermedades cardiovasculares, con énfasis sobre las interacciones plaqueta-miocardio para indicar las áreas futuras, actualmente bajo investigación, que puedan resultar y para precisar problemas potenciales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Schaper W, Winkler B: Of mice and men-the future of cardiovascular research in the molecular era. Cardiovasc Res 1998; 39: 3-7.

  2. Izaguirre Ávila R: Evolución del conocimiento sobre las plaquetas. Arch Inst Cardiol Mex 1997; 67: 511-520.

  3. Flores NA: Platelet activation during myocardial ischaemia: a contributory arrhythmogenic mechanism. Pharmacol Ther 1996; 72: 83-108.

  4. Flores NA, Sheridan DJ: The pathophysiological role of platelets during myocardial ischaemia. Cardiovasc Res 1994; 28: 295-302.

  5. Flores NA, Seghatchian MJ, Sheridan DJ: Platelet-mediated alterations in cardiac cellular electrophysiology. Blood Coagul Fibrinolysis 1991; 2: 367-371.

  6. Flores NA, Goulielmos NV, Seghatchian MJ, Sheridan DJ: Myocardial ischaemia induces platelet activation with adverse electrophysiological and arrhythmogenic effects. Cardiovasc Res 1994; 28: 1662-1671.

  7. Goulielmos NV, Enayat ZE, Sheridan DJ, Cohen H, Flores NA: Nitric oxide and prostacyclin modulate the alterations in cardiac action potential duration mediated by platelets during ischaemia. Cardiovasc Res 1995; 30: 788-798.

  8. Barr I, Cohen P, Berken A, Lown B: Thrombocythaemia and myocardial ischemia with normal coronary angiogram. Arch Intem Med 1974; 134: 528-533.

  9. Scheffer MG, Michiels JJ, Simoons ML, Roelandt JRTC: Thrombocythemia and coronary artery disease. Am Heart J 1991; 122: 573-575.

  10. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ: Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 1997; 79: 909-913.

  11. Van Kooten F, Ciabattoni G, Patrono C, Dippel DW, Koudstaal PJ: Platelet activation and lipid peroxidation in patients with acute ischemic stroke. Stroke 1997; 28: 1557-1563.

  12. Adgey AA: An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J 1998; 135: S43-S55.

  13. Ronner E, Dykun Y, van den Brand MJBM, van der Wieken LR, Simoons ML: Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Eur Heart J 1998; 19: 1608-1616.

  14. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al: Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis In Myocardial Infarction (TIMI)14 Trial. Circulation 1999; 99: 2720-2732.

  15. Coller BS: Monitoring platelet GPIIb/IIIa antagonist therapy. Circulation 1998; 97: 5-9.

  16. Scarborough RM, Kleiman NS, Phillips DR: Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999; 100: 437-444.

  17. Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, et al: Rapid assessment of platelet function with modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997; 96: 3860-3866.

  18. Yang LH, Fareed J: Vasomodulatory action of clopidogrel and ticlopidine. Thromb Res 1997; 86: 479-491.

  19. Joseph JE, Machin SJ: New antiplatelet drugs. Blood Rev 1997; 11: 178-190.

  20. Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, et al: Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422: 291-295.

  21. Savi P, Bornia J, Salel V, Delfaud M, Herbert JM: Characterization of P2x1 purinoreceptors on rat platelets: effect of clopidogrel. Br J Haematol 1997; 98: 880-886.

  22. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.

  23. Oberle S, Polte T, Abate A, Podhaisky H-P, Schröder H: Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res 1998; 82: 1016-1020.

  24. Wolin MS: Novel antioxidant action of aspirin may contribute to its beneficial cardiovascular actions. Circ Res 1998; 82: 1021-1022.

  25. Kuvin JT, Kimmelstiel CD: Infectious causes of atherosclerosis. Am Heart J 1999; 137: 216-226.

  26. Wever RMF, Lüscher TF, Cosentino F, Rabelink TJ: Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112.

  27. Flores NA, Stavrou BM, Sheridan DJ: The effects of diadenosine polyphosphates on the cardiovascular system. Cardiovasc Res 1999; 42: 15-26.

  28. Zamecknik PC, Kim B, Gao MJ, Taylor G, Blackburn GM: Analogues of diadenosine 5',5'’’-P1,P4-tetraphosphate (Ap4A) as potential anti-platelet-aggregation agents. Proc Natl Acad Sci USA 1992; 89: 2370-2373.

  29. Kim BK, Zamecknik P, Taylor G, Guo MJ, Blackburn GM: Antithrombotic effect of b,b’-monochloromethylene diadenosine 5',5'’’-P1,P4-tetraphosphate. Proc Natl Acad Sci USA 1992; 89: 11056-11058.

  30. Chan SW, Gallo SJ, Kim BK, Guo MJ, Blackburn GM, Zamecnik PC: P1,P4-dithio-P2, P3-monochloromethylene diadenosine 5',5'’’-Pl, P4-tetraphosphate: A novel antiplatelet agent. Proc Natl Acad Sci USA 1997; 94: 4034-4039.

  31. Bailey SR: Local drug delivery: current applications. Prog Cardiovasc Dis 1997; 40: 183-204.

  32. 32 Brieger D, Topol E: Local drug delivery systems and prevention of restenosis. Cardiovasc Res 1997; 35: 405-413.

  33. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, et al: Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-645.

  34. Pavlides GS, Barath P, Maginas A, Vasilikos V, Cokkinos DV, O’Neill WW: Intramural drug delivery by direct injection within the arterial wall: first clinical experience with a novel intracoronary delivery-infiltrator system. Cathet Cardiovasc Diagn 1997; 41: 287-292.

  35. Schwarzacher SP, Lim TT, Wang B, Kernoff RS, Niebauer J, Cooke JP, et al: Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation 1997; 95: 1863-1869.

  36. Waxman S, Moreno R, Rowe KA, Verrier RL: Persistent primary coronary dilation induced by transatrial delivery of nitroglycerin into the pericardial space: a novel approach for local cardiac drug delivery. J Am Coll Cardiol 1999; 33: 2073-2077.

  37. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ: Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997; 29: 808-816.

  38. McKenna CJ, Camrud AR, Sangiorgi G, Kwon HM, Edwards WD, Holmes DR Jr, et al: Fibrin-film stenting in a porcine coronary injury model: efficacy and safety compared with uncoated stents. J Am Coll Cardiol 1998; 31: 1434-1438.

  39. Gunn J, Cumberland D: Stent coatings and local drug delivery. State of the art. Eur Heart J 1999; 20: 1693-1700.

  40. Carter AJ, Scott D, Bailey L, Hoopes T, Jones R, Virmani R: Dose-response effects of32P radioactive stents in an atherosclerotic porcine coronary model. Circulation 1999; 100: 1548-1554.

  41. Dev V, Eigler N, Fishbein MC, Tian Y, Hickey A, Rechavia E, et al: Sustained local drug delivery to the arterial wall via biodegradable microspheres. Cathet Cardiovasc Diagn 1997; 41: 324-332.

  42. Van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, et al: Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-1697.

  43. Lovich MA, Edelman ER: Computational simulations of local vascular heparin deposition and distribution. Am J Physiol 1996; 271: H2014-H2024.

  44. Cazenave JP, Gachet C: Anti-platelet drugs: do they affect megakaryocytes? Baillieres Clin Haematol 1997; 10: 163-180.

  45. Hernandez-Antolin RA, Macaya-Miguel C: Perspectivas futuras del stent coronario. Rev Esp Cardiol 1997; 50 (Suppl 2): 95-106.

  46. Knight CJ, Panesar M, Wilson DJ, Patrineli A, Chronos N, Wright C, et al: Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis. Eur Heart J 1998; 19: 1239-1248.

  47. Schomig A, Neumann F-J, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089.

  48. Hobson AG, Sowinski KM: Ticlopidine and aspirin therapy following implantation of coronary artery stents. Ann Pharmacother 1997; 31: 770-772.

  49. Neumann FJ, Gawaz M, Dickfeld T, Wehinger A, Walter H, Blasini R, et al: Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol 1997; 29: 1515-1519.

  50. 50 Albiero R, Hall P, Itoh A, Blengino S, Nakamura S, Martini G, et al: Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation 1997; 95: 1145-1156.

  51. Elsner M, Peifer A, Drexler M, Wenzel C, Hebbeker C, Kasper W: Clinical outcome at six months of coronary stenting followed by ticlopidine monotherapy. Am J Cardiol 1998; 81: 147-151.

  52. Lafont A, Faxon D: Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res 1998; 39: 50-59.

  53. Fuster V, Poon M, Willerson JT: Learning from the transgenic mouse. Endothelium, adhesive molecules, and neointimal formation. Circulation 1998; 97: 16-18.

  54. Carmeliet P, Moons L, Collen D: Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res 1998; 39: 8-33.

  55. James JF, Hewett TE, Robbins J: Cardiac physiology in transgenic mice. Circ Res 1998; 82: 407-415.

  56. Ferrari R, Marber M, Cinca J: Cardiologists and their war on platelets. Eur Heart J 1999; 20: 557-558.

  57. Folts JD, Schafer AI, Loscalzo J, Willerson JT, Muller JE. A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. J Am Coll Cardiol 1999; 33: 295-303.

  58. Antiplatelet Triallists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.

  59. Choussat R, Montalescot G: Blocking platelets more: are we skating on thin ice? Heart 1998; 79: 5-6.

  60. Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, Szalony JA, Haas NF, et al: SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 1995; 91: 403-410.

  61. Ferguson JJ, Waly HM, Wilson JM: Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. Eur Heart J 1998; 19 (Suppl D): D3-D9.

  62. Chronos N, Vahanian A, Betriu A, Emanuelsson H, Goldberg S, Gulba D, et al: Use of abciximab in interventional cardiology. Eur Heart J 1998; 19 (Suppl D): D31-D39.

  63. Dzau VJ, von der Leyen HE, Morishita R: The concept and potentials of cardiovascular gene therapy. Dialogues in Cardiovasc Med 1997; 2: 3-17.

  64. Vale PR, Losordo DW, Tkebuchava T, Chan D, Milliken CE, Isner JM: Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping. J Am Coll Cardiol 1999; 34: 246-254.

  65. Marber MS, Wright MJ: What are the prospects for gene therapy in coronary artery disease? Dialogues in Cardiovasc Med 1997; 2: 33-36.

  66. Finkel T: Thinking globally, acting locally. The promise of cardiovascular gene therapy. Circ Res 1999; 84: 1471-1472.

  67. Arbustini E: What are the prospects for gene therapy in atherosclerosis? Dialogues in Cardiovasc Med 1997; 2: 20-27.

  68. D’Angelo DD, Davis MG, Houser WA, Eubank JJ, Ritchie ME, Dorn GW II: Characterization of 5' end of human thromboxane receptor gene. Organizational analysis and mapping of protein kinase C-responsive elements regulating expression in platelets. Circ Res 1995; 77: 466-474.

  69. Green FR, Watkins H: Genetic association studies in coronary disease: the case of GPIIb-IIIa polymorphisms. Eur Heart J 1999; 20: 706-708.

  70. Kastrati A, Schömig A, Seyfarth M, Koch W, Elezi S, Böttiger C, et al: P1A polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999; 99: 1005-1010.

  71. 71 Bashir G, Bakhai A, Gendi HE, Sumiya M, Flores NA, Violaris AG, et al: Correlation between the P1A2 platelet membrane Gp IIIa allele and platelet function for subjects with and without coronary artery disease. (Abstract) Clin Sci (Colch) 1999; 96: 3P.




2020     |     www.medigraphic.com